Exact Mass: 672.3541286000001
Exact Mass Matches: 672.3541286000001
Found 219 metabolites which its exact mass value is equals to given mass value 672.3541286000001
,
within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error
0.01 dalton.
l-685,458
C39H52N4O6 (672.3886652000001)
D004791 - Enzyme Inhibitors > D000091062 - Gamma Secretase Inhibitors and Modulators
Pyridin-3-ylmethyl N-[(2S,4S,5S)-4-hydroxy-5-[[(2S)-3-methyl-2-[[methyl(1,3-thiazol-4-ylmethyl)carbamoyl]amino]butanoyl]amino]-1,6-diphenylhexan-2-yl]carbamate
milbemycin alpha5
PA(12:0/20:4(6Z,8E,10E,14Z)-2OH(5S,12R))
C35H61O10P (672.4002135999999)
PA(12:0/20:4(6Z,8E,10E,14Z)-2OH(5S,12R)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(12:0/20:4(6Z,8E,10E,14Z)-2OH(5S,12R)), in particular, consists of one chain of one dodecanoyl at the C-1 position and one chain of Leukotriene B4 at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).
PA(20:4(6Z,8E,10E,14Z)-2OH(5S,12R)/12:0)
C35H61O10P (672.4002135999999)
PA(20:4(6Z,8E,10E,14Z)-2OH(5S,12R)/12:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(20:4(6Z,8E,10E,14Z)-2OH(5S,12R)/12:0), in particular, consists of one chain of one Leukotriene B4 at the C-1 position and one chain of dodecanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).
PA(12:0/20:4(6E,8Z,11Z,13E)-2OH(5S,15S))
C35H61O10P (672.4002135999999)
PA(12:0/20:4(6E,8Z,11Z,13E)-2OH(5S,15S)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(12:0/20:4(6E,8Z,11Z,13E)-2OH(5S,15S)), in particular, consists of one chain of one dodecanoyl at the C-1 position and one chain of 5(S),15(S)-Dihydroxyeicosatetraenoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).
PA(20:4(6E,8Z,11Z,13E)-2OH(5S,15S)/12:0)
C35H61O10P (672.4002135999999)
PA(20:4(6E,8Z,11Z,13E)-2OH(5S,15S)/12:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(20:4(6E,8Z,11Z,13E)-2OH(5S,15S)/12:0), in particular, consists of one chain of one 5(S),15(S)-Dihydroxyeicosatetraenoyl at the C-1 position and one chain of dodecanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).
PA(12:0/20:4(8Z,11Z,14Z,17Z)-2OH(5S,6R))
C35H61O10P (672.4002135999999)
PA(12:0/20:4(8Z,11Z,14Z,17Z)-2OH(5S,6R)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(12:0/20:4(8Z,11Z,14Z,17Z)-2OH(5S,6R)), in particular, consists of one chain of one dodecanoyl at the C-1 position and one chain of 5,6-Dihydroxyeicosatetraenoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).
PA(20:4(8Z,11Z,14Z,17Z)-2OH(5S,6R)/12:0)
C35H61O10P (672.4002135999999)
PA(20:4(8Z,11Z,14Z,17Z)-2OH(5S,6R)/12:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(20:4(8Z,11Z,14Z,17Z)-2OH(5S,6R)/12:0), in particular, consists of one chain of one 5,6-Dihydroxyeicosatetraenoyl at the C-1 position and one chain of dodecanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).
PA(i-12:0/20:4(6Z,8E,10E,14Z)-2OH(5S,12R))
C35H61O10P (672.4002135999999)
PA(i-12:0/20:4(6Z,8E,10E,14Z)-2OH(5S,12R)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(i-12:0/20:4(6Z,8E,10E,14Z)-2OH(5S,12R)), in particular, consists of one chain of one 10-methylundecanoyl at the C-1 position and one chain of Leukotriene B4 at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).
PA(20:4(6Z,8E,10E,14Z)-2OH(5S,12R)/i-12:0)
C35H61O10P (672.4002135999999)
PA(20:4(6Z,8E,10E,14Z)-2OH(5S,12R)/i-12:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(20:4(6Z,8E,10E,14Z)-2OH(5S,12R)/i-12:0), in particular, consists of one chain of one Leukotriene B4 at the C-1 position and one chain of 10-methylundecanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).
PA(i-12:0/20:4(6E,8Z,11Z,13E)-2OH(5S,15S))
C35H61O10P (672.4002135999999)
PA(i-12:0/20:4(6E,8Z,11Z,13E)-2OH(5S,15S)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(i-12:0/20:4(6E,8Z,11Z,13E)-2OH(5S,15S)), in particular, consists of one chain of one 10-methylundecanoyl at the C-1 position and one chain of 5(S),15(S)-Dihydroxyeicosatetraenoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).
PA(20:4(6E,8Z,11Z,13E)-2OH(5S,15S)/i-12:0)
C35H61O10P (672.4002135999999)
PA(20:4(6E,8Z,11Z,13E)-2OH(5S,15S)/i-12:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(20:4(6E,8Z,11Z,13E)-2OH(5S,15S)/i-12:0), in particular, consists of one chain of one 5(S),15(S)-Dihydroxyeicosatetraenoyl at the C-1 position and one chain of 10-methylundecanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).
PA(i-12:0/20:4(8Z,11Z,14Z,17Z)-2OH(5S,6R))
C35H61O10P (672.4002135999999)
PA(i-12:0/20:4(8Z,11Z,14Z,17Z)-2OH(5S,6R)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(i-12:0/20:4(8Z,11Z,14Z,17Z)-2OH(5S,6R)), in particular, consists of one chain of one 10-methylundecanoyl at the C-1 position and one chain of 5,6-Dihydroxyeicosatetraenoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).
PA(20:4(8Z,11Z,14Z,17Z)-2OH(5S,6R)/i-12:0)
C35H61O10P (672.4002135999999)
PA(20:4(8Z,11Z,14Z,17Z)-2OH(5S,6R)/i-12:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(20:4(8Z,11Z,14Z,17Z)-2OH(5S,6R)/i-12:0), in particular, consists of one chain of one 5,6-Dihydroxyeicosatetraenoyl at the C-1 position and one chain of 10-methylundecanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).
Muricellaxanthin
11-methoxy-10-(21-methyl-19-nor-alstophyllan-18-yl)-22-nor-alstophyllan-19-one|Des-N(alpha)-methylanhydromacralstonin|N1-demethyl-anhydromacralstonine
C42H48N4O4 (672.3675367999999)
7-Epigrandidon A|7-Epimer-Grandidone A|Epigrandidon 4
1,2-dihydro-5beta-hydroxy-21-methyl-6alpha,7alpha-epoxy-12beta-acetoxy-9,13,14-ortho-1alpha-(33E-pentadecenoate)-resiniferonol-36-oic acid|kirkinine C
ent-6beta,21;6alpha,7alpha-diepoxy-2,3-didehydro-(7betaC4,3beta)-3,4-dihydro-2H-spiro[aspidospermidine-7,5-pyrido[1,2,3:1,2,3]aspidospermidine]-3-carboxylic acid methyl ester|Isovoafolin|Voafolin|voafoline
C42H48N4O4 (672.3675367999999)
12-O-cinnamoyl-3beta,5alpha,8beta,12beta,14beta,17beta,20-heptahydroxy-(20S)-pregn-6-enyl-3-O-beta-D-cymaropyranoside|gymnepregoside G
(2S,3S,4R)-10-de-O-carbamoyl-12-O-carbamoyl-Nbeta-acetylstreptothricin E
1beta,2beta,3,beta4,beta,5beta,6beta,7alpha,26-octahydroxy-furost-20(22),25(27)-dien-26-O-beta-D-glucopyranoside|tupisteroside B
16beta-hydroxy-17-acetoxy-ent-kauran-19-oic acid(6-O-beta-D-xylopyranosyl-beta-D-glucopyranosyl) ester
acide zanhique triacetate dimethyl ester|triacetate dimethylester de lacide zanhique|triacetate du methylester de lacide zanhique
3beta,14beta,15beta-trihydroxypregn-5-en-20-one 3-O-beta-D-glucopyranosyl-(1->2)-beta-D-glucopyranoside|cynaforroside J
Arg Arg Arg Trp
Arg Arg Trp Arg
Arg Trp Arg Arg
Trp Arg Arg Arg
DGMG 18:5
PS-PI
C29H53O15P (672.3121917999999)
1,4-BIS[2-[4-[N,N-DI(P-TOLYL)AMINO]PHENYL]VINYL]BENZENE
2-(chloromethyl)oxirane,formaldehyde,4-[2-(4-hydroxyphenyl)propan-2-yl]phenol,2-methyloxirane,4-nonylphenol,oxirane
C39H57ClO7 (672.3792601999999)
(R)-6-[L-2-(2-amino-1,4,5,6-tetrahydro-4-pyrimidinyl)glycine]viomycin
C25H46N13O9+3 (672.3541286000001)
[(10E,14E,16E)-3,21,24-trihydroxy-5,6,11,13,22-pentamethyl-2-oxospiro[3,7,19-trioxatetracyclo[15.6.1.14,8.020,24]pentacosa-10,14,16,22-tetraene-6,2-oxane]-4-yl] 2-methylhexanoate
D000890 - Anti-Infective Agents > D000977 - Antiparasitic Agents > D000871 - Anthelmintics D010575 - Pesticides > D007306 - Insecticides D016573 - Agrochemicals
PA(12:0/20:4(6Z,8E,10E,14Z)-2OH(5S,12R))
C35H61O10P (672.4002135999999)
PA(20:4(6Z,8E,10E,14Z)-2OH(5S,12R)/12:0)
C35H61O10P (672.4002135999999)
PA(12:0/20:4(6E,8Z,11Z,13E)-2OH(5S,15S))
C35H61O10P (672.4002135999999)
PA(20:4(6E,8Z,11Z,13E)-2OH(5S,15S)/12:0)
C35H61O10P (672.4002135999999)
PA(12:0/20:4(8Z,11Z,14Z,17Z)-2OH(5S,6R))
C35H61O10P (672.4002135999999)
PA(20:4(8Z,11Z,14Z,17Z)-2OH(5S,6R)/12:0)
C35H61O10P (672.4002135999999)
PA(i-12:0/20:4(6Z,8E,10E,14Z)-2OH(5S,12R))
C35H61O10P (672.4002135999999)
PA(20:4(6Z,8E,10E,14Z)-2OH(5S,12R)/i-12:0)
C35H61O10P (672.4002135999999)
PA(i-12:0/20:4(6E,8Z,11Z,13E)-2OH(5S,15S))
C35H61O10P (672.4002135999999)
PA(20:4(6E,8Z,11Z,13E)-2OH(5S,15S)/i-12:0)
C35H61O10P (672.4002135999999)
PA(i-12:0/20:4(8Z,11Z,14Z,17Z)-2OH(5S,6R))
C35H61O10P (672.4002135999999)
PA(20:4(8Z,11Z,14Z,17Z)-2OH(5S,6R)/i-12:0)
C35H61O10P (672.4002135999999)
Nbeta-Acetylstreptothricin E
A natural product found in Streptomyces sp. I08A 1776.
lumutinine A
C42H48N4O4 (672.3675367999999)
A natural product found in Alstonia macrophylla.
lumutinine B
C42H48N4O4 (672.3675367999999)
A natural product found in Alstonia macrophylla.
[1-[(2-heptanoyloxy-3-hydroxypropoxy)-hydroxyphosphoryl]oxy-3-hydroxypropan-2-yl] (10Z,13Z,16Z,19Z)-docosa-10,13,16,19-tetraenoate
C35H61O10P (672.4002135999999)
[1-hydroxy-3-[hydroxy-(3-hydroxy-2-nonanoyloxypropoxy)phosphoryl]oxypropan-2-yl] (8Z,11Z,14Z,17Z)-icosa-8,11,14,17-tetraenoate
C35H61O10P (672.4002135999999)
[1-hydroxy-3-[hydroxy-(3-hydroxy-2-propanoyloxypropoxy)phosphoryl]oxypropan-2-yl] (14Z,17Z,20Z,23Z)-hexacosa-14,17,20,23-tetraenoate
C35H61O10P (672.4002135999999)
[1-hydroxy-3-[hydroxy-(3-hydroxy-2-pentanoyloxypropoxy)phosphoryl]oxypropan-2-yl] (12Z,15Z,18Z,21Z)-tetracosa-12,15,18,21-tetraenoate
C35H61O10P (672.4002135999999)
[1-hydroxy-3-[hydroxy-(3-hydroxy-2-undecanoyloxypropoxy)phosphoryl]oxypropan-2-yl] (6Z,9Z,12Z,15Z)-octadeca-6,9,12,15-tetraenoate
C35H61O10P (672.4002135999999)
[1-hydroxy-3-[hydroxy-[3-hydroxy-2-[(Z)-tridec-9-enoyl]oxypropoxy]phosphoryl]oxypropan-2-yl] (7Z,10Z,13Z)-hexadeca-7,10,13-trienoate
C35H61O10P (672.4002135999999)
[1-hydroxy-3-[hydroxy-(3-hydroxy-2-tridecanoyloxypropoxy)phosphoryl]oxypropan-2-yl] (4Z,7Z,10Z,13Z)-hexadeca-4,7,10,13-tetraenoate
C35H61O10P (672.4002135999999)
[1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-nonanoyloxypropan-2-yl] (8Z,11Z,14Z,17Z)-icosa-8,11,14,17-tetraenoate
C35H61O10P (672.4002135999999)
[1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-heptanoyloxypropan-2-yl] (10Z,13Z,16Z,19Z)-docosa-10,13,16,19-tetraenoate
C35H61O10P (672.4002135999999)
[1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-propanoyloxypropan-2-yl] (14Z,17Z,20Z,23Z)-hexacosa-14,17,20,23-tetraenoate
C35H61O10P (672.4002135999999)
[1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-pentanoyloxypropan-2-yl] (12Z,15Z,18Z,21Z)-tetracosa-12,15,18,21-tetraenoate
C35H61O10P (672.4002135999999)
[1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-[(Z)-tridec-9-enoyl]oxypropan-2-yl] (7Z,10Z,13Z)-hexadeca-7,10,13-trienoate
C35H61O10P (672.4002135999999)
[1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-undecanoyloxypropan-2-yl] (6Z,9Z,12Z,15Z)-octadeca-6,9,12,15-tetraenoate
C35H61O10P (672.4002135999999)
[1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-tridecanoyloxypropan-2-yl] (4Z,7Z,10Z,13Z)-hexadeca-4,7,10,13-tetraenoate
C35H61O10P (672.4002135999999)
[2-[(7E,9E,11E,13E)-hexadeca-7,9,11,13-tetraenoyl]oxy-3-phosphonooxypropyl] (4E,7E,10E,13E,16E)-nonadeca-4,7,10,13,16-pentaenoate
[2-[(5E,7E,9E,11E,13E)-hexadeca-5,7,9,11,13-pentaenoyl]oxy-3-phosphonooxypropyl] (7E,10E,13E,16E)-nonadeca-7,10,13,16-tetraenoate
[(2R)-1-[[(2S)-2,3-dihydroxypropoxy]-hydroxyphosphoryl]oxy-3-undecanoyloxypropan-2-yl] (6E,9E,12E,15E)-octadeca-6,9,12,15-tetraenoate
C35H61O10P (672.4002135999999)
[1-[[(2S)-2,3-dihydroxypropoxy]-hydroxyphosphoryl]oxy-3-tridecanoyloxypropan-2-yl] (7E,9E,11E,13E)-hexadeca-7,9,11,13-tetraenoate
C35H61O10P (672.4002135999999)
[(2S)-3-[[(2R)-2,3-dihydroxypropoxy]-hydroxyphosphoryl]oxy-2-undecanoyloxypropyl] (9E,11E,13E,15E)-octadeca-9,11,13,15-tetraenoate
C35H61O10P (672.4002135999999)
[(2S)-3-[[(2R)-2,3-dihydroxypropoxy]-hydroxyphosphoryl]oxy-2-undecanoyloxypropyl] (6E,9E,12E,15E)-octadeca-6,9,12,15-tetraenoate
C35H61O10P (672.4002135999999)
[(2R)-1-[[(2S)-2,3-dihydroxypropoxy]-hydroxyphosphoryl]oxy-3-undecanoyloxypropan-2-yl] (9E,11E,13E,15E)-octadeca-9,11,13,15-tetraenoate
C35H61O10P (672.4002135999999)
[1-[[(2S)-2,3-dihydroxypropoxy]-hydroxyphosphoryl]oxy-3-[(E)-tridec-8-enoyl]oxypropan-2-yl] (9E,11E,13E)-hexadeca-9,11,13-trienoate
C35H61O10P (672.4002135999999)
phosphatidylserine 28:3(1-)
A 3-sn-phosphatidyl-L-serine(1-) in which the acyl groups at C-1 and C-2 contain 28 carbons in total and 3 double bonds.
(3s)-n-(2-{[(3as,7r,7as)-4,7-dihydroxy-3h,3ah,6h,7h,7ah-imidazo[4,5-c]pyridin-2-yl]amino}-4,5-dihydroxy-6-[(c-hydroxycarbonimidoyloxy)methyl]oxan-3-yl)-6-{[(3s)-3,6-diamino-1-hydroxyhexylidene]amino}-3-[(1-hydroxyethylidene)amino]hexanimidic acid
10-[9-butyl-8-(4-carboxy-3-methylbuta-1,3-dien-1-yl)-9-[(4-methoxy-4-oxobut-2-enoyl)oxy]-3-methyl-1,7-dioxaspiro[5.5]undecan-2-yl]-5-hydroxy-4,8-dimethyldeca-2,6,8-trienoic acid
n-[10-benzyl-1,8,11-trihydroxy-3-(1h-indol-3-ylmethyl)-6,13-dimethyl-4,14-dioxo-3h,6h,7h,10h,13h,16h,17h,18h,18ah-pyrrolo[2,1-f]1-oxa-4,7,10,13-tetraazacyclohexadecan-7-yl]butanimidic acid
C36H44N6O7 (672.3271314000001)
(1r,2r,6s,7s,8r,10s,11r,12r,14s,16s,17r,18r)-6,7-dihydroxy-8-(hydroxymethyl)-4,18-dimethyl-5-oxo-14-[(1e)-pentadec-1-en-1-yl]-16-(prop-1-en-2-yl)-9,13,15,19-tetraoxahexacyclo[12.4.1.0¹,¹¹.0²,⁶.0⁸,¹⁰.0¹²,¹⁶]nonadec-3-en-17-yl acetate
(1s,2r,3r,7s,9s,10r,11r,12s,14s,15r,16s,17s,22s,23s,24s,25r)-14,25-bis(acetyloxy)-3,22-dihydroxy-11,15,17,22,23-pentamethyl-4,21-dioxo-8,20-dioxaheptacyclo[13.10.0.0²,¹².0⁵,¹¹.0⁷,⁹.0¹⁶,²⁴.0¹⁹,²³]pentacos-18-en-10-yl 2-methylpropanoate
1-[(1s,12s,13r,18r)-6-methoxy-20-methyl-7-{[(1s,12s,13r,18r)-3,16,20-trimethyl-15-oxa-3,20-diazapentacyclo[10.7.1.0²,¹⁰.0⁴,⁹.0¹³,¹⁸]icosa-2(10),4,6,8,16-pentaen-17-yl]methyl}-15-oxa-3,20-diazapentacyclo[10.7.1.0²,¹⁰.0⁴,⁹.0¹³,¹⁸]icosa-2(10),4,6,8,16-pentaen-17-yl]ethanone
C42H48N4O4 (672.3675367999999)
(1r,2r,6s,7s,8r,10s,11s,12r,14s,16s,17r,18r)-6,7-dihydroxy-8-(hydroxymethyl)-4,18-dimethyl-5-oxo-14-[(1e)-pentadec-1-en-1-yl]-16-(prop-1-en-2-yl)-9,13,15,19-tetraoxahexacyclo[12.4.1.0¹,¹¹.0²,⁶.0⁸,¹⁰.0¹²,¹⁶]nonadec-3-en-17-yl acetate
(2r,3s,5s)-2-{[(3s,5s,6r)-6-{[(1s,3as,7s,9ar,11ar)-3a-hydroxy-1-(1-hydroxyethyl)-9a,11a-dimethyl-1h,2h,3h,3bh,4h,6h,7h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthren-7-yl]oxy}-5-hydroxy-4-methoxy-2-methyloxan-3-yl]oxy}-6-(hydroxymethyl)oxane-2,3,4,5-tetrol
2,4a-dimethyl 10,11-bis(acetyloxy)-9-[(acetyloxy)methyl]-2,6a,6b,9,12a-pentamethyl-1,3,4,5,6,7,8,8a,10,11,12,12b,13,14b-tetradecahydropicene-2,4a-dicarboxylate
(2s,3s,4s,5r,6r)-6-{[(1r,3as,3bs,5s,5as,7s,9as,11as)-9a,11a-dimethyl-1-[(1s)-1-[(2s,3s)-3-(2-methylpropyl)oxiran-2-yl]ethyl]-5-(sulfooxy)-1h,2h,3h,3ah,3bh,4h,5h,5ah,6h,7h,8h,9h,11h-cyclopenta[a]phenanthren-7-yl]oxy}-3,4,5-trihydroxyoxane-2-carboxylic acid
9-benzyl-5,8,11,14-tetrahydroxy-6-(1h-indol-3-ylmethyl)-15-isopropyl-1-methyl-3,12-bis(2-methylpropyl)-1,4,7,10,13-pentaazacyclopentadeca-4,7,10,13-tetraen-2-one
C38H52N6O5 (672.3998981999999)
10-o-acetylaglaine b
C38H44N2O9 (672.3046654000001)
{"Ingredient_id": "HBIN000176","Ingredient_name": "10-o-acetylaglaine b","Alias": "NA","Ingredient_formula": "C38H44N2O9","Ingredient_Smile": "Not Available","Ingredient_weight": "NA","OB_score": "NA","CAS_id": "NA","SymMap_id": "NA","TCMID_id": "307","TCMSP_id": "NA","TCM_ID_id": "NA","PubChem_id": "NA","DrugBank_id": "NA"}
4-epiaglain a
C38H44N2O9 (672.3046654000001)
{"Ingredient_id": "HBIN010355","Ingredient_name": "4-epiaglain a","Alias": "NA","Ingredient_formula": "C38H44N2O9","Ingredient_Smile": "CCC(C)C(=O)NC1CCCN1C(=O)C2C(C3(C(C2(C4=C(O3)C=C(C=C4OC)OC)O)OC(=O)C)C5=CC=C(C=C5)OC)C6=CC=CC=C6","Ingredient_weight": "672.8 g/mol","OB_score": "NA","CAS_id": "NA","SymMap_id": "NA","TCMID_id": "6823","TCMSP_id": "NA","TCM_ID_id": "NA","PubChem_id": "101118316","DrugBank_id": "NA"}
aglaine a
C38H44N2O9 (672.3046654000001)
{"Ingredient_id": "HBIN014859","Ingredient_name": "aglaine a","Alias": "NA","Ingredient_formula": "C38H44N2O9","Ingredient_Smile": "Not Available","Ingredient_weight": "NA","OB_score": "NA","CAS_id": "NA","SymMap_id": "NA","TCMID_id": "738","TCMSP_id": "NA","TCM_ID_id": "NA","PubChem_id": "NA","DrugBank_id": "NA"}
(2r)-n-[(2s)-1-[(1r,9r,10r,11s,12s)-12-(acetyloxy)-1-hydroxy-3,5-dimethoxy-9-(4-methoxyphenyl)-10-phenyl-8-oxatricyclo[7.2.1.0²,⁷]dodeca-2,4,6-triene-11-carbonyl]pyrrolidin-2-yl]-2-methylbutanimidic acid
C38H44N2O9 (672.3046654000001)
methyl (1r,9r,12r,13e,18s)-13-ethylidene-5-[(1r,9r,10s,12r,13e,16s,17r)-13-ethylidene-5-methoxy-8-methyl-18-oxo-8,15-diazahexacyclo[14.2.1.0¹,⁹.0²,⁷.0¹⁰,¹⁵.0¹²,¹⁷]nonadeca-2(7),3,5-trien-4-yl]-4-oxo-8,15-diazapentacyclo[10.5.1.0¹,⁹.0²,⁷.0⁹,¹⁵]octadeca-2,5,7-triene-18-carboxylate
(2e)-n-[4-({hydroxy[(1s,9s,10s,11r,12r)-1-hydroxy-3,5-dimethoxy-12-(methoxycarbonyl)-9-(4-methoxyphenyl)-10-phenyl-8-oxatricyclo[7.2.1.0²,⁷]dodeca-2,4,6-trien-11-yl]methylidene}amino)butyl]-2-methylbut-2-enimidic acid
C38H44N2O9 (672.3046654000001)
(1r,2s,7s,8s)-3,3,5,8,10,10-hexamethoxy-7-(prop-2-en-1-yl)-11-{[(1r,2r,4r)-1,8,8-trimethoxy-7-oxo-5-(prop-2-en-1-yl)bicyclo[2.2.2]oct-5-en-2-yl]methyl}tricyclo[6.2.2.0²,⁷]dodeca-5,11-diene-4,9-dione
(2s)-n-[(1r)-4-carbamimidamido-1-({3-[(2s,5s)-3,6-dihydroxy-5-[3-(n-hydroxyformamido)propyl]-2,5-dihydropyrazin-2-yl]propyl}(hydroxy)carbamoyl)butyl]-5-(n-hydroxyacetamido)-2-[(1-hydroxypropylidene)amino]pentanimidic acid
(1s,2s,7s,8r)-3,3,5,8,10,10-hexamethoxy-7-(prop-2-en-1-yl)-11-{[(1s,2s,4s)-1,8,8-trimethoxy-7-oxo-5-(prop-2-en-1-yl)bicyclo[2.2.2]oct-5-en-2-yl]methyl}tricyclo[6.2.2.0²,⁷]dodeca-5,11-diene-4,9-dione
(2s)-n-[(2s)-1-[(1s,9s,10r,11r,12s)-12-(acetyloxy)-1-hydroxy-3,5-dimethoxy-9-(4-methoxyphenyl)-10-phenyl-8-oxatricyclo[7.2.1.0²,⁷]dodeca-2,4,6-triene-11-carbonyl]pyrrolidin-2-yl]-2-methylbutanimidic acid
C38H44N2O9 (672.3046654000001)
(4as,9s,10as,11'as)-5',7',8-trihydroxy-4',7-diisopropyl-1,1,4a,8',8',11'a-hexamethyl-2,3,4,10',10a,11'-hexahydro-9'h-spiro[phenanthrene-9,2'-phenanthro[3,4-d][1,3]dioxole]-5,6,6',10-tetrone
(3's,6'r,13'r,16's,23'r,24'as)-6'-[(2s)-4-amino-2-hydroxybutyl]-1',4',7',11',14',17',23'-heptahydroxy-3',13',16'-tris(hydroxymethyl)-3',6',9',10',13',16',22',23',24',24'a-decahydrospiro[cyclopropane-1,19'-pyrrolo[2,1-i]1,4,7,10,13,16,19-heptaazacyclodocosan]-20'-one
(4as,7'ar,9s,10as,11'as)-5',6-dihydroxy-4',7-diisopropyl-1,1,4a,8',8',11'a-hexamethyl-2,3,4,7'a,9',10',10a,11'-octahydrospiro[phenanthrene-9,2'-phenanthro[3,4-d][1,3]dioxole]-5,6',7',8,10-pentone
n-[(3s,6r,7s,10r,13r,18as)-10-benzyl-1,8,11-trihydroxy-3-(1h-indol-3-ylmethyl)-6,13-dimethyl-4,14-dioxo-3h,6h,7h,10h,13h,16h,17h,18h,18ah-pyrrolo[2,1-f]1-oxa-4,7,10,13-tetraazacyclohexadecan-7-yl]butanimidic acid
C36H44N6O7 (672.3271314000001)
n-[(2s)-1-[(1r,9r,10r,11s,12r)-12-(acetyloxy)-1-hydroxy-3,5-dimethoxy-9-(4-methoxyphenyl)-10-phenyl-8-oxatricyclo[7.2.1.0²,⁷]dodeca-2,4,6-triene-11-carbonyl]pyrrolidin-2-yl]-2-methylbutanimidic acid
C38H44N2O9 (672.3046654000001)
(2s)-n-[(2s)-1-[(1r,9r,10s,11r,12r)-12-(acetyloxy)-1-hydroxy-3,5-dimethoxy-9-(4-methoxyphenyl)-10-phenyl-8-oxatricyclo[7.2.1.0²,⁷]dodeca-2,4,6-triene-11-carbonyl]pyrrolidin-2-yl]-2-methylbutanimidic acid
C38H44N2O9 (672.3046654000001)
(4as,7'as,9r,10as,11'as)-5',6-dihydroxy-4',7-diisopropyl-1,1,4a,8',8',11'a-hexamethyl-2,3,4,7'a,9',10',10a,11'-octahydrospiro[phenanthrene-9,2'-phenanthro[3,4-d][1,3]dioxole]-5,6',7',8,10-pentone
n-[(2s)-1-[(1r,9r,10s,11r,12s)-12-(acetyloxy)-1-hydroxy-3,5-dimethoxy-9-(4-methoxyphenyl)-10-phenyl-8-oxatricyclo[7.2.1.0²,⁷]dodeca-2,4,6-triene-11-carbonyl]pyrrolidin-2-yl]-2-methylbutanimidic acid
C38H44N2O9 (672.3046654000001)
methyl (8r,13e,14s,16s,17s,18s)-13-ethylidene-17-[(1e)-2-[(1s,12s,13r,18r)-7-methoxy-3,20-dimethyl-15-oxa-3,20-diazapentacyclo[10.7.1.0²,¹⁰.0⁴,⁹.0¹³,¹⁸]icosa-2(10),4,6,8,16-pentaen-17-yl]ethenyl]-1,11-diazapentacyclo[12.3.1.0²,⁷.0⁸,¹⁷.0¹¹,¹⁶]octadeca-2,4,6-triene-18-carboxylate
C42H48N4O4 (672.3675367999999)
3,6-diamino-n-(5-{[2-({4,7-dihydroxy-3h,3ah,6h,7h,7ah-imidazo[4,5-c]pyridin-2-yl}amino)-4,5-dihydroxy-6-[(c-hydroxycarbonimidoyloxy)methyl]oxan-3-yl]-c-hydroxycarbonimidoyl}-4-[(1-hydroxyethylidene)amino]pentyl)hexanimidic acid
10-[8-(4-carboxy-3-methylbuta-1,3-dien-1-yl)-9-[(3-carboxyprop-2-enoyl)oxy]-3-methyl-9-pentyl-1,7-dioxaspiro[5.5]undecan-2-yl]-5-hydroxy-4,8-dimethyldeca-2,6,8-trienoic acid
(2r)-n-[(2s)-1-[(1r,9r,10r,11s,12r)-12-(acetyloxy)-1-hydroxy-3,5-dimethoxy-9-(4-methoxyphenyl)-10-phenyl-8-oxatricyclo[7.2.1.0²,⁷]dodeca-2,4,6-triene-11-carbonyl]pyrrolidin-2-yl]-2-methylbutanimidic acid
C38H44N2O9 (672.3046654000001)
(2s)-n-[(2s)-1-[(1r,9r,10s,11s,12s)-12-(acetyloxy)-1-hydroxy-3,5-dimethoxy-9-(4-methoxyphenyl)-10-phenyl-8-oxatricyclo[7.2.1.0²,⁷]dodeca-2,4,6-triene-11-carbonyl]pyrrolidin-2-yl]-2-methylbutanimidic acid
C38H44N2O9 (672.3046654000001)
6-(6-{[(4-carboxy-3-hydroxy-3-methylbutanoyl)oxy]methyl}-11-hydroxy-3a,6,9a,11a-tetramethyl-3,4,7,10-tetraoxo-1h,2h,5h,5ah,8h,9h,11h-cyclopenta[a]phenanthren-1-yl)-2-methylhept-2-enoic acid
n-[(2s)-1-[(1r,9r,10r,11s,12s)-12-(acetyloxy)-1-hydroxy-3,5-dimethoxy-9-(4-methoxyphenyl)-10-phenyl-8-oxatricyclo[7.2.1.0²,⁷]dodeca-2,4,6-triene-11-carbonyl]pyrrolidin-2-yl]-2-methylbutanimidic acid
C38H44N2O9 (672.3046654000001)
(2s)-1-[(2s)-2-({[(2r)-1-[(2s)-2-{[(2s)-2-amino-1-hydroxy-4-methylpentylidene]amino}-3-(1h-indol-3-yl)propanoyl]pyrrolidin-2-yl](hydroxy)methylidene}amino)-3-phenylpropanoyl]-5-oxopyrrolidine-2-carboxylic acid
C36H44N6O7 (672.3271314000001)
(2e)-n-[4-({[(1r,9r,10s,11r,12r)-12-(acetyloxy)-1-hydroxy-3,5-dimethoxy-9-(4-methoxyphenyl)-10-phenyl-8-oxatricyclo[7.2.1.0²,⁷]dodeca-2,4,6-trien-11-yl](hydroxy)methylidene}amino)butyl]-2-methylbut-2-enimidic acid
C38H44N2O9 (672.3046654000001)
12-hydroxy-2-{[(5-hydroxy-3,4-dimethoxy-6-methyloxan-2-yl)oxy]methyl}-9-[(3-hydroxy-4-methoxy-6-methyloxan-2-yl)oxy]-3,12-dimethyl-4,17-dioxabicyclo[14.1.0]heptadeca-6,14-diene-5,13-dione
(4as,9s,10as,11'as)-5',6,7'-trihydroxy-4',7-diisopropyl-1,1,4a,8',8',11'a-hexamethyl-2,3,4,10',10a,11'-hexahydro-9'h-spiro[phenanthrene-9,2'-phenanthro[3,4-d][1,3]dioxole]-5,6',8,10-tetrone
(2s)-n-[(2s)-1-[(1s,9s,10r,11s,12r)-12-(acetyloxy)-1-hydroxy-3,5-dimethoxy-9-(4-methoxyphenyl)-10-phenyl-8-oxatricyclo[7.2.1.0²,⁷]dodeca-2,4,6-triene-11-carbonyl]pyrrolidin-2-yl]-2-methylbutanimidic acid
C38H44N2O9 (672.3046654000001)
n-[(2s)-1-[(1r,9r,10r,11r,12r)-12-(acetyloxy)-1-hydroxy-3,5-dimethoxy-9-(4-methoxyphenyl)-10-phenyl-8-oxatricyclo[7.2.1.0²,⁷]dodeca-2,4,6-triene-11-carbonyl]pyrrolidin-2-yl]-2-methylbutanimidic acid
C38H44N2O9 (672.3046654000001)
2-[(5-{[3a,5a-dihydroxy-9a,11a-dimethyl-1-(6-oxopyran-3-yl)-dodecahydro-1h-cyclopenta[a]phenanthren-7-yl]oxy}-1-hydroxy-5-oxopentylidene)amino]-5-carbamimidamidopentanoic acid
C35H52N4O9 (672.3734102000001)
(1s,2s,4s,5r,8r,9s,10z,12r)-11-({[(2r,3r,4r,5r)-3-(acetyloxy)-4,5-dihydroxyoxan-2-yl]oxy}methyl)-5-hydroxy-8-isopropyl-12-methoxy-1,5-dimethyl-15-oxatricyclo[10.2.1.0⁴,⁹]pentadeca-6,10,13-trien-2-yl (2e)-3-(1-methylimidazol-4-yl)prop-2-enoate
C35H48N2O11 (672.3257937999999)
(2e,6r)-6-[(1r,3ar,5ar,6r,9as,11r,11ar)-6-({[(3s)-4-carboxy-3-hydroxy-3-methylbutanoyl]oxy}methyl)-11-hydroxy-3a,6,9a,11a-tetramethyl-3,4,7,10-tetraoxo-1h,2h,5h,5ah,8h,9h,11h-cyclopenta[a]phenanthren-1-yl]-2-methylhept-2-enoic acid
(1s,2s,4r,5r,8s,9s,10z,12r)-11-({[(2r,3s,4r,5r)-3-(acetyloxy)-4,5-dihydroxyoxan-2-yl]oxy}methyl)-5-hydroxy-8-isopropyl-12-methoxy-1,5-dimethyl-15-oxatricyclo[10.2.1.0⁴,⁹]pentadeca-6,10,13-trien-2-yl (2e)-3-(1-methylimidazol-4-yl)prop-2-enoate
C35H48N2O11 (672.3257937999999)
5-[(deca-2,4-dienoyloxy)methyl]-3,3a,4,5,6,8,10a-heptahydroxy-2,10-dimethyl-8-(prop-1-en-2-yl)-decahydrocyclohexa[e]azulen-7-yl benzoate
(1r,1's,2'r,5's,6r,10's,11'r,14'r,15's,23's)-2,2,2',6,10',14',23'-heptamethyl-18'-(sulfooxy)-6'-oxaspiro[cyclohexane-1,7'-hexacyclo[12.11.0.0²,¹¹.0⁵,¹⁰.0¹⁵,²³.0¹⁷,²²]pentacosane]-17',19',21'-trien-21'-yl(hydroxy)acetic acid
(1s,2r,3s,6e,9s,12r,14e,16r)-12-hydroxy-2-({[(2r,3r,4r,5r,6r)-5-hydroxy-3,4-dimethoxy-6-methyloxan-2-yl]oxy}methyl)-9-{[(2s,3r,4s,6r)-3-hydroxy-4-methoxy-6-methyloxan-2-yl]oxy}-3,12-dimethyl-4,17-dioxabicyclo[14.1.0]heptadeca-6,14-diene-5,13-dione
[(1s,2s,4s,8s,9s,12s,13r,14r,16r)-16-hydroxy-7,9,13-trimethyl-6-(3-methyl-4-{[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}butyl)-5-oxapentacyclo[10.8.0.0²,⁹.0⁴,⁸.0¹³,¹⁸]icosa-6,18-dien-14-yl]oxidanesulfonic acid
(3s)-n-[(2r,3r,4s,5r,6r)-2-{[(3as,7r,7as)-4,7-dihydroxy-3h,3ah,6h,7h,7ah-imidazo[4,5-c]pyridin-2-yl]amino}-4-hydroxy-5-(c-hydroxycarbonimidoyloxy)-6-(hydroxymethyl)oxan-3-yl]-6-{[(3s)-3,6-diamino-1-hydroxyhexylidene]amino}-3-[(1-hydroxyethylidene)amino]hexanimidic acid
5',6-dihydroxy-4',7-diisopropyl-1,1,4a,8',8',11'a-hexamethyl-2,3,4,7'a,9',10',10a,11'-octahydrospiro[phenanthrene-9,2'-phenanthro[3,4-d][1,3]dioxole]-5,6',7',8,10-pentone
(2e,4s,5s,6e,8e)-10-[(2r,3s,6s,8s,9r)-9-butyl-8-[(1e,3e)-4-carboxy-3-methylbuta-1,3-dien-1-yl]-9-{[(2e)-4-methoxy-4-oxobut-2-enoyl]oxy}-3-methyl-1,7-dioxaspiro[5.5]undecan-2-yl]-5-hydroxy-4,8-dimethyldeca-2,6,8-trienoic acid
(2s)-2-[(5-{[(1r,3as,3br,5as,7s,9ar,9bs,11ar)-3a,5a-dihydroxy-9a,11a-dimethyl-1-(6-oxopyran-3-yl)-dodecahydro-1h-cyclopenta[a]phenanthren-7-yl]oxy}-1-hydroxy-5-oxopentylidene)amino]-5-carbamimidamidopentanoic acid
C35H52N4O9 (672.3734102000001)
(3s)-n-[(2r,3r,4s,5r,6r)-2-{[(3as,7r,7as)-4,7-dihydroxy-3h,3ah,6h,7h,7ah-imidazo[4,5-c]pyridin-2-yl]amino}-4,5-dihydroxy-6-[(c-hydroxycarbonimidoyloxy)methyl]oxan-3-yl]-6-{[(3s)-3,6-diamino-1-hydroxyhexylidene]amino}-3-[(1-hydroxyethylidene)amino]hexanimidic acid
6'-(4-amino-2-hydroxybutyl)-1',4',7',11',14',17',23'-heptahydroxy-3',13',16'-tris(hydroxymethyl)-3',6',9',10',13',16',22',23',24',24'a-decahydrospiro[cyclopropane-1,19'-pyrrolo[2,1-i]1,4,7,10,13,16,19-heptaazacyclodocosan]-20'-one
(1s,4s,7s,10s,13s,16s)-10-benzyl-13-(1-hydroxyethyl)-16-methyl-7-{1-[(2-methylbut-3-en-2-yl)oxy]ethyl}-4-(sec-butyl)-18-thia-3,6,9,12,15,20-hexaazabicyclo[15.2.1]icosa-2,5,8,14,17(20)-pentaene-2,5,8,14-tetrol
C34H52N6O6S (672.3668852000001)
(2s,3s,3ar,4s,5r,6s,6as,7r,8r,10r,10ar,10bs)-5-{[(2e,4e)-deca-2,4-dienoyloxy]methyl}-3,3a,4,5,6,8,10a-heptahydroxy-2,10-dimethyl-8-(prop-1-en-2-yl)-decahydrocyclohexa[e]azulen-7-yl benzoate
n-[4-({[12-(acetyloxy)-1-hydroxy-3,5-dimethoxy-9-(4-methoxyphenyl)-10-phenyl-8-oxatricyclo[7.2.1.0²,⁷]dodeca-2,4,6-trien-11-yl](hydroxy)methylidene}amino)butyl]-2-methylbut-2-enimidic acid
C38H44N2O9 (672.3046654000001)
(3r,6r,9r,12r,15r)-9-benzyl-5,8,11,14-tetrahydroxy-6-(1h-indol-3-ylmethyl)-15-isopropyl-1-methyl-3,12-bis(2-methylpropyl)-1,4,7,10,13-pentaazacyclopentadeca-4,7,10,13-tetraen-2-one
C38H52N6O5 (672.3998981999999)
(4as,9r,10as,11'as)-5',6,7'-trihydroxy-4',7-diisopropyl-1,1,4a,8',8',11'a-hexamethyl-2,3,4,10',10a,11'-hexahydro-9'h-spiro[phenanthrene-9,2'-phenanthro[3,4-d][1,3]dioxole]-5,6',8,10-tetrone
(2e,4s,5s,6e,8e)-10-[(2r,3s,6s,8s,9r)-8-[(1e,3e)-4-carboxy-3-methylbuta-1,3-dien-1-yl]-9-{[(2e)-3-carboxyprop-2-enoyl]oxy}-3-methyl-9-pentyl-1,7-dioxaspiro[5.5]undecan-2-yl]-5-hydroxy-4,8-dimethyldeca-2,6,8-trienoic acid
2,4a-dimethyl (2s,4ar,6as,6br,8as,9r,10r,11s,12ar,12br,14bs)-10,11-bis(acetyloxy)-9-[(acetyloxy)methyl]-2,6a,6b,9,12a-pentamethyl-1,3,4,5,6,7,8,8a,10,11,12,12b,13,14b-tetradecahydropicene-2,4a-dicarboxylate
n-{1-[12-(acetyloxy)-1-hydroxy-3,5-dimethoxy-9-(4-methoxyphenyl)-10-phenyl-8-oxatricyclo[7.2.1.0²,⁷]dodeca-2,4,6-triene-11-carbonyl]pyrrolidin-2-yl}-2-methylbutanimidic acid
C38H44N2O9 (672.3046654000001)
1-(2-{[(1-{2-[(2-amino-1-hydroxy-4-methylpentylidene)amino]-3-(1h-indol-3-yl)propanoyl}pyrrolidin-2-yl)(hydroxy)methylidene]amino}-3-phenylpropanoyl)-5-oxopyrrolidine-2-carboxylic acid
C36H44N6O7 (672.3271314000001)
1-[6-methoxy-20-methyl-7-({3,16,20-trimethyl-15-oxa-3,20-diazapentacyclo[10.7.1.0²,¹⁰.0⁴,⁹.0¹³,¹⁸]icosa-2(10),4,6,8,16-pentaen-17-yl}methyl)-15-oxa-3,20-diazapentacyclo[10.7.1.0²,¹⁰.0⁴,⁹.0¹³,¹⁸]icosa-2(10),4,6,8,16-pentaen-17-yl]ethanone
C42H48N4O4 (672.3675367999999)
1-(7-{[4,5-dihydroxy-6-(hydroxymethyl)-3-{[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}oxan-2-yl]oxy}-3,3a-dihydroxy-9a,11a-dimethyl-1h,2h,3h,3bh,4h,6h,7h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthren-1-yl)ethanone
(4as,7'as,9s,10as,11'as)-5',6-dihydroxy-4',7-diisopropyl-1,1,4a,8',8',11'a-hexamethyl-2,3,4,7'a,9',10',10a,11'-octahydrospiro[phenanthrene-9,2'-phenanthro[3,4-d][1,3]dioxole]-5,6',7',8,10-pentone
5',6,7'-trihydroxy-4',7-diisopropyl-1,1,4a,8',8',11'a-hexamethyl-2,3,4,10',10a,11'-hexahydro-9'h-spiro[phenanthrene-9,2'-phenanthro[3,4-d][1,3]dioxole]-5,6',8,10-tetrone
methyl (13e)-13-ethylidene-17-(2-{7-methoxy-3,20-dimethyl-15-oxa-3,20-diazapentacyclo[10.7.1.0²,¹⁰.0⁴,⁹.0¹³,¹⁸]icosa-2(10),4,6,8,16-pentaen-17-yl}ethenyl)-1,11-diazapentacyclo[12.3.1.0²,⁷.0⁸,¹⁷.0¹¹,¹⁶]octadeca-2,4,6-triene-18-carboxylate
C42H48N4O4 (672.3675367999999)
(1s,2s,7s,8r)-3,3,5,8,10,10-hexamethoxy-7-(prop-2-en-1-yl)-11-{[(1s,2r,4s)-1,8,8-trimethoxy-7-oxo-5-(prop-2-en-1-yl)bicyclo[2.2.2]oct-5-en-2-yl]methyl}tricyclo[6.2.2.0²,⁷]dodeca-5,11-diene-4,9-dione
3-amino-n-(4-amino-5-{[2-({4,7-dihydroxy-3h,3ah,6h,7h,7ah-imidazo[4,5-c]pyridin-2-yl}amino)-4-hydroxy-5-(c-hydroxycarbonimidoyloxy)-6-(hydroxymethyl)oxan-3-yl]-c-hydroxycarbonimidoyl}pentyl)-6-[(1-hydroxyethylidene)amino]hexanimidic acid
(2s)-n-[(1r)-4-carbamimidamido-1-({3-[(2s,5s)-3,6-dihydroxy-5-[3-(n-hydroxyacetamido)propyl]-2,5-dihydropyrazin-2-yl]propyl}(hydroxy)carbamoyl)butyl]-5-(n-hydroxyacetamido)-2-[(1-hydroxyethylidene)amino]pentanimidic acid
(2r)-n-[(2s)-1-[(1r,9r,10r,11r,12r)-12-(acetyloxy)-1-hydroxy-3,5-dimethoxy-9-(4-methoxyphenyl)-10-phenyl-8-oxatricyclo[7.2.1.0²,⁷]dodeca-2,4,6-triene-11-carbonyl]pyrrolidin-2-yl]-2-methylbutanimidic acid
C38H44N2O9 (672.3046654000001)